Download: Article on production and purification of an antibody therapeutic
Michiel Ultee, Chief Scientific Officer at Laureate Biopharmaceutical Services, kindly provided this article entitled, ‘Production and Purification of a PER.C6-Expressed IgM Antibody Therapeutic.’
Immunoglobulin M (IgM) antibodies hold a great deal of potential as cancer therapeutics, but a number of misconceptions about IgMs have prevented their more widespread adoption. “For example, some people believe that these antibodies are too large to be effective, that their expression levels in bioproduction systems are too low to be economically feasible, and that they are unstable and too difficult to purify.”
Because of this, alternative expression systems have become available to express protein therapeutics. “For example, the PER.C6 human cell line… has been extensively developed for producing recombinant proteins.”
Using that cell line, the authors successfully “expressed IgMs at higher titers that are functional and stable,” by using “a straightforward and rapid stable cell-line generation method.”
The article goes on to describe the technology transfer and scale-up of a process for a PER.C6 line expressing the PAT-SM6 (SM6) IgM antibody, outlining the production, scalability, and purification processes for that antibody.
Download the article here for more information on this process!
Michiel will be speaking at the upcoming Cell Culture World Congress USA on the topic, ‘Stainless vs. Single-Use – A Case Study of Production of a Non-Antibody Glycoprotein Therapeutic.’ Register now to hear him share his insights on this topic, or download the brochure for more information.
